ReviewStem cell reviews and reports2025
Exercise-Activated Mesenchymal Stem Cells: A Translational Strategy for Age-Related Sarcopenia Management.
Review in Stem cell reviews and reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Exercise rejuvenates the "muscle-heart" crosstalk: skeletal muscle-derived exosomal miRNAs in cardiac aging.Frontiers in cardiovascular medicine · 2026Review
- Exerkine-loaded exosomes in muscle aging: a nexus of exercise, regeneration, and crosstalk.Frontiers in cell and developmental biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Age-related Sarcopenia is a progressive, age-related disorder characterized by the loss of muscle strength, mass, and function, which is associated with an increased risk of falls and mortality and reduced quality of life, particularly in older adults. The pathophysiology of sarcopenia is complex, primarily driven by an imbalance between anabolic and catabolic muscle homeostasis. Effective interventions of sarcopenia is crucial to reverse or delay the progression of muscle disorder. Cell-based therapy is emerging as an innovative approach for sarcopenia. Owing to their multipotent differentiation capacity, self-renewal ability, and immunomodulatory effects, mesenchymal stem cells (MSCs) offer a promising therapeutic avenue for sarcopenia through mechanisms such as tissue regeneration, paracrine signaling, and immune regulation. However, despite their potential, MSC-based therapies face limitations, including low engraftment efficiency and poor post-transplant cell survival. Emerging evidence suggests that combining MSC transplantation with exercise intervention may enhance therapeutic efficacy. In this review, we aimed to summarize the synergistic mechanisms underlying MSC-exercise interactions, with a focus on how exercise modulates MSC migration, differentiation, and muscle regenerative capacity. By addressing the limitations of standalone MSC therapy, this combinatorial strategy may pave the way for more effective age-related sarcopenia management. Finally, we highlight future research directions, underscoring the need for optimized exercise regimens, refined MSC delivery protocols, and translational studies to facilitate the clinical application of this integrated approach.
Indexed as
Identifiers
40900288What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.